TW200509967A - Compositions and methods for WT1 specific immunotherapy - Google Patents

Compositions and methods for WT1 specific immunotherapy

Info

Publication number
TW200509967A
TW200509967A TW093112333A TW93112333A TW200509967A TW 200509967 A TW200509967 A TW 200509967A TW 093112333 A TW093112333 A TW 093112333A TW 93112333 A TW93112333 A TW 93112333A TW 200509967 A TW200509967 A TW 200509967A
Authority
TW
Taiwan
Prior art keywords
compositions
methods
polypeptide
specific immunotherapy
presenting
Prior art date
Application number
TW093112333A
Other languages
English (en)
Inventor
Alexander Gaiger
Patricia D Mcneill
Nomalie Jaya
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of TW200509967A publication Critical patent/TW200509967A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW093112333A 2003-04-30 2004-04-30 Compositions and methods for WT1 specific immunotherapy TW200509967A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/427,717 US7553494B2 (en) 2001-08-24 2003-04-30 WT1 fusion proteins

Publications (1)

Publication Number Publication Date
TW200509967A true TW200509967A (en) 2005-03-16

Family

ID=33449619

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093112333A TW200509967A (en) 2003-04-30 2004-04-30 Compositions and methods for WT1 specific immunotherapy

Country Status (16)

Country Link
US (2) US7553494B2 (zh)
EP (1) EP1617863A4 (zh)
JP (1) JP2007515393A (zh)
KR (1) KR20060054176A (zh)
CN (1) CN1816349A (zh)
AU (1) AU2004238226A1 (zh)
BR (1) BRPI0409879A (zh)
CA (1) CA2523943A1 (zh)
CO (1) CO5700788A2 (zh)
MA (1) MA27873A1 (zh)
MX (1) MXPA05011755A (zh)
NO (1) NO20055347L (zh)
RU (1) RU2005137167A (zh)
TW (1) TW200509967A (zh)
WO (1) WO2004100870A2 (zh)
ZA (1) ZA200509609B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI480552B (zh) * 2006-08-14 2015-04-11 Academia Sinica 胃液蛋白分析於胃癌鑑定之方法

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4422903B2 (ja) * 1998-07-31 2010-03-03 株式会社癌免疫研究所 癌抑制遺伝子ｗｔ１の産物に基づく癌抗原
US7329410B1 (en) * 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7901693B2 (en) * 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20040097703A1 (en) * 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US20050260217A1 (en) * 2004-03-04 2005-11-24 Corixa Corporation Co-encapsulated WT1 polypeptide and immunostimulant microsphere formulations and methods thereof
EP2565201B1 (en) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
EP3834836A1 (en) * 2006-04-10 2021-06-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and uses thereof
EP2980219B1 (en) * 2006-12-28 2018-11-14 International Institute of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
AU2012227350C1 (en) * 2006-12-28 2015-11-12 International Institute Of Cancer Immunology, Inc. HLA-A*1101-Restricted WT1 peptide and pharmaceutical composition comprising the same
DK2119778T3 (en) * 2007-02-27 2016-01-25 Int Inst Cancer Immunology Inc A process for the activation of the helper T cell, and composition for use in this process
CL2008001491A1 (es) * 2007-05-24 2008-11-28 Glaxosmithkline Biolog Sa Composicion liofilizada que comprende uno o mas antigenos y un agonista del receptor de tipo toll 9 (tlr9); y procedimiento de preparacion.
WO2009006479A2 (en) 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
AR076284A1 (es) * 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
BR112013024395B1 (pt) * 2011-03-23 2021-10-26 Fred Hutchinson Cancer Research Center Composições adotivas de imunoterapia celular e método para fabricação da dita composição
US9074000B2 (en) * 2011-04-01 2015-07-07 Memorial Sloan Kettering Cancer Center T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
CA2861206C (en) 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof
WO2014031178A1 (en) * 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
KR20230038607A (ko) * 2012-12-13 2023-03-20 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ｗｔ１ 백신
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CN105377291B (zh) 2013-01-15 2019-04-02 纪念斯隆凯特林癌症中心 免疫原性wt-1肽和其使用方法
CN103961702B (zh) * 2013-02-05 2019-04-09 日东电工株式会社 粘膜给予用wt1肽癌症疫苗组合物
KR20140100419A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 조성물
CA2841014A1 (en) * 2013-02-05 2014-08-05 Nitto Denko Corporation Tape preparation of wt1 peptide cancer vaccine for transdermal administration
WO2015129790A1 (ja) 2014-02-26 2015-09-03 株式会社バイオイミュランス Ｗｔ１抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤
US10739344B2 (en) * 2014-12-29 2020-08-11 West Virginia University Zinc finger linker (ZnFL) antibody
US10695385B2 (en) * 2015-06-25 2020-06-30 National University Corporation Kobe University Oral cancer vaccine
CN116327902A (zh) 2015-11-20 2023-06-27 纪念斯隆凯特林癌症中心 用于治疗癌症的方法和组合物
EP3394092A1 (en) * 2015-12-23 2018-10-31 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
CN105713874A (zh) * 2016-01-29 2016-06-29 深圳市中美康士生物科技有限公司 一种抗肿瘤相关抗原wt1特异性ctl及其制备方法
EP3549957A4 (en) 2016-11-30 2020-08-05 Sumitomo Dainippon Pharma Co., Ltd. WT1-HELPER PEPTIDE AND COMBINATION OF THE SAYING PEPTIDE AND A CANCER ANTIGEN PEPTIDE CONJUGATE
JPWO2018181648A1 (ja) 2017-03-30 2020-02-13 大日本住友製薬株式会社 Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体
MX2021003660A (es) 2018-09-28 2021-05-28 Sumitomo Pharma Co Ltd Composicion inyectable.
EP4151227A1 (en) * 2020-05-12 2023-03-22 Sumitomo Pharma Co., Ltd. Pharmaceutical composition for treating cancer
JPWO2023017836A1 (zh) 2021-08-12 2023-02-16
CN113730562B (zh) * 2021-09-10 2024-06-04 中国人民解放军陆军军医大学 以壳聚糖修饰plga的wt1多肽纳米粒疫苗及其制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3393867B2 (ja) 1989-11-13 2003-04-07 マサチユーセツツ・インステイテユート・オブ・テクノロジー ウィルムス腫瘍遺伝子の位置決定と特徴付け
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
AU671971B2 (en) 1991-11-29 1996-09-19 Chiron Corporation Anti-cancer immunotherapeutic vector constructs
US5679356A (en) 1992-07-08 1997-10-21 Schering Corporation Use of GM-CSF as a vaccine adjuvant
JP2735986B2 (ja) 1992-10-16 1998-04-02 株式会社セラリカ野田 癌抑制遺伝子ｗｔの産物に対する抗体
EP0692973A1 (en) 1993-03-15 1996-01-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Peptide coated dendritic cells as immunogens
US5705159A (en) 1993-08-31 1998-01-06 John Wayne Cancer Institute Immunoreactive peptide sequence from a 43 KD human cancer antigen
US5622835A (en) 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
US5670317A (en) 1995-05-08 1997-09-23 Sloan-Kettering Institute For Cancer Research Diagnostic test for the desmoplastic small round cell tumor
EP0841068B1 (en) 1995-06-01 2006-07-12 Kishimoto, Tadamitsu Leukemic cell growth inhibitor containing antisense oligonucleotide derivative against wilms' tumor gene (wt1)
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
JP4789095B2 (ja) 1997-07-16 2011-10-05 治夫 杉山 ウイルムス腫瘍遺伝子（ｗｔ１）に対する発現阻害物質を含んで成る固形腫瘍治療剤
JPH1189596A (ja) 1997-09-19 1999-04-06 Takara Shuzo Co Ltd Ｒｎａ量の測定方法並びに測定キット
JPH1189599A (ja) 1997-09-24 1999-04-06 Haruo Sugiyama 補正競合ｒｔ−ｐｃｒ法によるヒトｗｔ１発現定量法
EP1068339B1 (en) 1998-04-01 2008-07-23 The Governors of the University of Alberta Compositions and methods for protein secretion
WO1999058135A1 (en) 1998-05-11 1999-11-18 The Salk Institute For Biological Studies Compositions for the treatment of tumors, and uses thereof
JP4422903B2 (ja) 1998-07-31 2010-03-03 株式会社癌免疫研究所 癌抑制遺伝子ｗｔ１の産物に基づく癌抗原
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US20030039635A1 (en) * 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
AU6407899A (en) 1998-09-30 2000-04-17 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
AU7859900A (en) 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
NZ521430A (en) 2000-02-22 2004-04-30 Corixa Corp Compositions comprising 1-4 antigenic peptide fragments of the Wilms' tumour gene product for treatment or prevention of malignant mesothelioma
CN1314359A (zh) 2000-03-17 2001-09-26 上海博德基因开发有限公司 一种新的多肽——肿瘤抑制因子63和编码这种多肽的多核苷酸
WO2001094629A2 (en) 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
WO2002000677A1 (en) 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
EP1356060B1 (en) 2000-09-18 2005-12-14 Genencor International, Inc. Twin-arginine translocation in bacillus
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI480552B (zh) * 2006-08-14 2015-04-11 Academia Sinica 胃液蛋白分析於胃癌鑑定之方法

Also Published As

Publication number Publication date
CO5700788A2 (es) 2006-11-30
BRPI0409879A (pt) 2006-05-16
JP2007515393A (ja) 2007-06-14
KR20060054176A (ko) 2006-05-22
AU2004238226A1 (en) 2004-11-25
NO20055347L (no) 2006-01-27
NO20055347D0 (no) 2005-11-11
US7553494B2 (en) 2009-06-30
WO2004100870A2 (en) 2004-11-25
CA2523943A1 (en) 2004-11-25
CN1816349A (zh) 2006-08-09
RU2005137167A (ru) 2006-06-27
MXPA05011755A (es) 2006-02-17
US7915393B2 (en) 2011-03-29
EP1617863A2 (en) 2006-01-25
WO2004100870A3 (en) 2005-03-31
US20090312403A1 (en) 2009-12-17
MA27873A1 (fr) 2006-05-02
ZA200509609B (en) 2007-04-25
EP1617863A4 (en) 2007-12-19
US20040018204A1 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
TW200509967A (en) Compositions and methods for WT1 specific immunotherapy
AU9660801A (en) Compositions and methods for wt1 specific immunotherapy
WO2003037060A3 (en) Compositions and methods for wt1 specific immunotherapy
TW200606176A (en) Compositions and methods for wt1 specific immunotherapy
WO2001025273A3 (en) Compositions and methods for wt1 specific immunotherapy
IL258880A (en) Compounds of diarylhydantoin
IN2012DN01964A (zh)
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
WO2004101762A3 (en) Detection and treatment of cancers of the colon
WO2003024302A3 (en) Detection and treatment of cancers of breast
WO2003024304A3 (en) Detection and treatment of cancers of the liver
WO2003081250A8 (en) Novel compositions and methods in cancer associated with altered expression of prlr
WO2004069209A3 (en) Compositions and methods for increasing the sensitivity of apoptosis-resistant tumor cells to inducers of apoptosis
WO2003079977A3 (en) Novel compositions and methods in cancer associated with altered expression of mcm3ap
WO2024083925A3 (en) Novel anti-napi2b antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof